Lansoprazole Capsule, Delayed Release
Product Images NDC 67877-274

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 67877-274). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lansoprazole-30s-bottle (Lansoprazole 30s Bottle)

Label for Lansoprazole 15 mg delayed-release capsules, USP. The label notes each pink and green capsule contains 15 mg of Lansoprazole as enteric coated granules, imprinted with "264" in white ink. Manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ. The label includes a pharmacist instruction box and indicates a 30-capsule package.*

FDA Label Image

Lansoprazole-90s-bottle (Lansoprazole 90s Bottle)

Lansoprazole 30 mg delayed-release capsules label for oral use, provided in a 90-capsule quantity by Ascend Laboratories, LLC. The label includes dosage form and strength, manufacturer details (Alkem Laboratories Ltd., India), a barcode, and instructions to dispense the accompanying Medication Guide. The capsules are pink and black, imprinted with '263,' and packaged with storage and safety instructions.*

FDA Label Image

Lansoprazole-figure-1 (Lansoprazole Figure 1)

A line chart showing the mean severity of day heartburn over days from the start of treatment. The graph compares three groups: Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, with severity rated from 0 (none) to 3 (severe). Both Lansoprazole doses show a decrease in heartburn severity compared to placebo over the treatment period.*

FDA Label Image

Lansoprazole-figure-2 (Lansoprazole Figure 2)

A line graph titled 'Mean Severity of Night Heartburn By Study Day For Evaluable Patients.' It shows the mean severity of night heartburn over approximately 60 days from the start of treatment. The y-axis ranges from 0 to 1.8, indicating severity levels (0=None, 1=Mild, 2=Moderate, 3=Severe). Three lines represent groups: Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, showing a decline in heartburn severity over time, with Lansoprazole groups showing lower severity than placebo.*

FDA Label Image

Lansoprazole-str (Lansoprazole Str)

Chemical structure of lansoprazole, showing its molecular composition including benzimidazole and substituted pyridine rings with sulfoxide and trifluoromethoxy functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.